Security key
97382D501
Windtree Therapeutics, Inc. - Common Stock, par value $0.001 per share (WINT)
CUSIP: 97382D501
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 313,688
- Total 13F value
- $108,690
- Share change
- +150,580
- SEC-reported price per share
- $0.35
- Number of holders
- 13
- Value change
- -$276,250
- Number of buys
- 11
- Number of sells
- 3
- Shares outstanding
- 11,315,765
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
13
Top holders
10
WINT full security history
Ownership snapshot
Full 13F holder table
WINDTREE THERAPEUTICS INC /DE/ SEC filings
WINDTREE THERAPEUTICS INC /DE/ company facts
Broader feeds
Ownership snapshot
Top reported holders of WINT - Windtree Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
James Huang
Comparable rows
1/15
Latest evidence
08 Oct 2024
13F
13D/G
3/4/5
Lead comparable stake: 2.6%
14 rows are not safely comparable across share classes.
13D/G row: ARMISTICE CAPITAL, LLC
Showing 1-6 of 15 holder rows.
Quick read
ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 2.6%.
1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership
Top 1
ARMISTICE CAPITAL, LLC
2.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC |
13F
13D/G
Company
|
2.6%
Reported 13D/G
· 31 Dec 2024
|
$375,230
157,000 shares
|
— | 30 Sep 2024 |
| Center Laboratories, Inc. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
$2,527,492
2,782,352 shares
mixed-class rows
|
— | 20 May 2020 |
| Bioengine Capital Inc. |
3/4/5
10%+ Owner
|
—
mixed-class rows
|
—
304,176 shares
mixed-class rows
|
— | 20 May 2020 |
| James Huang |
3/4/5
Director
|
—
mixed-class rows
|
$3,819,976
5,970,058 shares
mixed-class rows
|
— | 22 Feb 2023 |
| John P. Hamill |
3/4/5
SVP & CFO
|
—
denominator unverified
|
$74,249
72,800 shares
|
— | 26 Jul 2022 |
| Craig Fraser |
3/4/5
President and CEO, Director
|
—
mixed-class rows
|
$59,032
12,669 shares
mixed-class rows
|
— | 08 Oct 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
13
Shares
313,688
Rows available
13
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
7
Q4 2024 holders
13
Holder diff
6
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|